🟠 Moderate Evidence
Women with moderate pre-cancerous cervical cells (cervical intraepithelial neoplasia grade 2, or CIN 2) do not face increased cancer risk if treatment is delayed up to six months, according to a target trial emulation study published in the Annals of Internal Medicine. The finding suggests that routine immediate excision of CIN 2 lesions may be unnecessary for many women, potentially sparing thousands from invasive procedures each year.
Key takeaways
- Excision of CIN 2 within six months did not reduce three-year cervical cancer risk compared with continued surveillance alone
- Delaying treatment substantially reduced the number of unnecessary cervical excisions without compromising safety
- The findings may reshape clinical practice guidelines for managing moderate cervical dysplasia, particularly in lower-risk cases
- Individualised risk stratification rather than automatic treatment is likely safer and more cost-effective
Study at a Glance
| Source | Annals of Internal Medicine |
| Study type | Target trial emulation (observational cohort analysis) |
| Population | Women with cervical intraepithelial neoplasia grade 2 (CIN 2) |
| Follow-up period | Three years |
| Primary outcome | Cervical cancer incidence; secondary outcome: treatment avoidance |
Treatment outcomes in CIN 2: Excision versus surveillance at three years
Comparison of cervical cancer incidence and unnecessary procedures, treatment within 6 months vs. surveillance continuation
Source: Annals of Internal Medicine, 2026 | Georgian Medical Journal News
Rethinking immediate treatment of cervical dysplasia
Cervical intraepithelial neoplasia (CIN) represents a spectrum of precancerous changes. CIN 1 (mild) often regresses spontaneously, while CIN 3 (severe) carries substantial cancer risk and warrants prompt excision. CIN 2 has occupied an ambiguous middle ground in clinical practice: some guidelines recommend immediate treatment, whilst others permit observation. The natural history of CIN 2 remains incompletely understood, with regression, persistence, and progression all documented in longitudinal cohorts.
This target trial emulation study, published in the Annals of Internal Medicine, directly addressed whether the timing of excision alters outcomes. The researchers compared women who received excision within six months to those who continued surveillance without immediate intervention. The key finding: no statistically significant difference in three-year cervical cancer incidence emerged between the two strategies.
Reducing unnecessary procedures without compromising safety
Beyond cancer risk, the study quantified a substantial reduction in unnecessary cervical excisions among women assigned to surveillance. Since CIN 2 can spontaneously regress—particularly lower-risk CIN 2 detected in younger women—delaying excision allows the natural immune response to clear precancerous lesions without surgical intervention. This distinction matters clinically and psychologically: excisional procedures carry known morbidities, including cervical incompetence in future pregnancies, infection, and bleeding.
The findings suggest that individualised risk stratification—rather than automatic excision—may be the prudent approach. Lower-risk CIN 2 cases (younger age, no immunosuppression, negative HPV co-infections) are particularly suitable for surveillance, whilst higher-risk presentations may still warrant prompt treatment. This aligns with recent guidance from the World Health Organization on cervical cancer prevention, which emphasises tailored management based on individual risk.
Clinical practice implications and guideline evolution
Current cervical cancer screening programmes in many high-income countries have achieved dramatic reductions in incidence and mortality through systematic screening (Pap smear, HPV testing) followed by risk-based management. However, overtreatment remains a substantial problem: many women receive excisional procedures for lesions that would have regressed naturally. The new Annals of Internal Medicine evidence provides robust data to support more conservative thresholds.
This evidence may prompt revision of clinical practice guidelines in the coming months. Professional organisations including the American College of Obstetricians and Gynaecologists (ACOG) and the European Society for Gynaecological Oncology (ESGO) maintain detailed CIN management algorithms; the absence of cancer risk difference at six months should inform these recommendations. For clinical practice, the implication is clear: CIN 2 detection should trigger risk assessment, not automatic excision.
Excision of CIN 2 within six months did not reduce three-year cervical cancer incidence compared with continued surveillance, suggesting that delayed or selective treatment may be safe and substantially reduces unnecessary procedures.
— Annals of Internal Medicine, 2026
What this means
Frequently asked questions
What is CIN 2 and how is it detected?
Cervical intraepithelial neoplasia grade 2 (CIN 2) is a moderate form of precancerous change detected on cervical biopsy following abnormal Pap smear or HPV test results. It represents dysplasia affecting up to two-thirds of the cervical epithelium. Routine screening programmes identify abnormal cytology, which then triggers colposcopy (magnified visualisation) and biopsy for histological grading.
Why was immediate treatment previously the standard approach?
Historical data suggested that CIN 2 could progress to invasive cancer if left untreated. Excisional procedures (loop electrosurgical excision, or LEEP) became standard practice to prevent progression. However, recent epidemiological evidence shows that a substantial proportion of CIN 2 regresses spontaneously, particularly in younger women and those with competent immune function. The new trial emulation data now quantifies that this regression occurs without increased cancer risk, even with six months of delay.
Is surveillance safe for all women with CIN 2?
No. The study suggests surveillance is safe for CIN 2 overall, but clinicians should identify higher-risk subgroups (older age, immunosuppression, persistent HPV infection, atypical features on histology) who may benefit from prompt excision. All women under surveillance must have reliable access to follow-up testing and clear clinical protocols in place. Those unable to comply with surveillance schedules or follow-up testing may still be better served by excision.
The shift from automatic excision to risk-based CIN 2 management represents a maturing of cervical cancer prevention strategy. As screening programmes have reduced the absolute burden of cervical cancer in high-income countries, attention has turned to eliminating unnecessary treatment—a goal that benefits patient wellbeing without compromising safety. Future research should examine how best to implement risk stratification algorithms in clinical practice and to extend these findings to lower-income settings where cervical cancer incidence remains substantially higher.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
